Competitor Analysis: Tissue Growth Factors
The present Competitive Intelligence Report about tissue growth factors provides a competitor evaluation in the field of molecules such as proteins, peptides, antibodies, DNA, RNA, cells and small molecules directly or indirectly stimulating tissue growth as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The classical tissue factors typically are proteins used for tissue repair and growth stimulation. Among the approved products are the growth factors PDGF, IGF, EGF, BMP and FGF. One of the commercially most successful growth factors is BMP-2 from Medtronic and Pfizer (ex Wyeth) with annual sales of nearly US$ 800 mln and prospect for further growth by use in additional indications. Growth factors are used for treatment of growth failure, skin wounds and ulcers, corneal damage, oral mucositis or to stimulate bone growth. Further growth factors such as HGF, VEGF, TGF, NGF, GDF and quite a number of neurotrophic factors are under development. Apart from proteins as the classical drugs, other classes of compounds are also under development such as small molecules to stimulate growth factor receptors or antibodies to block inhibitory pathways, thereby inducing functional recovery. Furthermore, engineered peptides mimicking growth factors, cells engineered to express growth factors or simply plasmids for growth factors are under development.
The report includes a compilation of currently active projects in research and development of proteins, peptides, antibodies, DNA, RNA, cells and small molecules directly or indirectly stimulating tissue growth and repair. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
- Hepatocyte Growth Factor (HGF) / Scatter Factor (SF)
- Insulin-like Growth Factor (IGF)
- Vascular Endothelial Growth Factor (VEGF)
- Epidermal Growth Factor (EGF)
- Platelet-Derived Growth Factor (PDGF)
- Fibroblast Growth Factor (FGF)
- Transforming Growth Factor (TGF)
- Growth Factors for Bone, Dental, Cartilage and Tendon Repair
- Nerve Growth Factor (NGF)
- Neurotrophic Growth Factors
- Various Other Growth Factors
- About La Merie
- Acceleron
- Acologix
- Acorda Therapeutics
- ActoGeniX
- Advitech
- Alizyme
- Alnylam Pharmaceuticals
- Alseres Pharmaceuticals
- Ambrx
- Amgen
- AnGes MG
- Angion Biomedica
- ARCA biopharma
- Argenta Biotechnologies
- Ark Therapeutics
- ArmaGen Technologies
- Astellas Pharma
- Asterion
- Auckland Uniservices
- Baxter
- Beijing SL Pharmaceuticals
- Bharat Biotech
- Bioactive Bone Substitutes (BBS)
- Biogen Idec
- Biopharm
- BioMimetic Therapeutics
- Bio-Sidus
- Biosurface Engineering Technologies
- Biovitrum
- Bone Biologics
- Bonenta
- BrainStorm Cell Therapeutics
- C3 Jian
- Capstone Therapeutics
- CardioVascular BioTherapeutics
- Cardium Therapeutics
- Celgene
- NeNeRx Biopharma
- CeraPedics
- Ceregene
- Cytomedix
- Daewoong Pharmaceutical Co.
- Daiichi Sankyo
- DePuy Spine
- Dompé
- Dr. Reddy's Laboratories
- Edward Life Sciences
- Eli Lilly
- ENKAM
- Gene Vector Laboratory
- Genzyme
- GI Company
- GlaxoSmithKline (GSK)
- Immuron
- Insmed
- Ipsen
- Johnson & Johnson (Ortho-McNeil Pharmaceuticals)
- Kaken Pharmaceutical Co
- Kirin (Kyowa Hakko Kirin Pharma)
- Kolon Life Sciences
- Krenitsky Pharmaceuticals
- Kringle Pharmaceuticals
- Kuros Biosurgery
- Lay Line Genomics
- Lupin Pharmaceuticals
- Maruho
- Medtronic
- Merck & Co
- Merck Serono
- Metabolic Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Neuren Pharmaceuticals
- Neurobiological Technologies
- NeuroNova
- Neurosearch
- Neurotech
- Nobel Biocare
- NsGene
- Osteohealth
- Oxford Biomedica
- Oy Lx Therapies
- Pfizer (Wyeth)
- Phage Biotechnology
- Phytopharm
- Renovo
- Roche
- Sangamo Biosciences
- Sanofi-Aventis
- Scil Proteins
- Scil Technology
- Shire
- Sinobiomed
- Spectrum Pharmaceuticals
- Stem Cell Therapeutics
- Taisho Toyama Pharmaceutical Co
- Takeda Pharmaceutical Co
- Teva Pharmaceutical Industries (CoGenesys)
- TissueGene
- ToolGen
- Tornier
- Transition Therapeutics
- Trillium Therapeutics
- Tripep
- Trophogen
- UCB
- Uni-Bio Science Group
- USV
- Vical
- ViroMed
- Zelos Therapeutics
- Zymogenetics
The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.
